Study identifier:ACH228-002
ClinicalTrials.gov identifier:NCT05047484
EudraCT identifier:N/A
CTIS identifier:N/A
A Randomized, Double-Blind, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACH-0145228 in Healthy Participants
Healthy
Phase 1
Yes
ALXN2050, Placebo
All
45
Interventional
25 Years - 55 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Basic Science
Verified 01 Jul 2024 by Alexion Pharmaceuticals
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: Cohort 1: 40 mg ALXN2050/Placebo Participants randomized to receive ALXN2050 or placebo twice daily (BID) on Day 1 through Day 14 in a fasted state. | Drug: ALXN2050 Powder-in-capsule (PIC). Other Name: ACH-0145228 (formerly) Other Name: ACH-5228 Drug: Placebo PIC. |
| Experimental: Cohort 2: 80 mg ALXN2050/Placebo Participants randomized to receive ALXN2050 or placebo BID on Day 1 through Day 14 in a fasted state. | Drug: ALXN2050 Powder-in-capsule (PIC). Other Name: ACH-0145228 (formerly) Other Name: ACH-5228 Drug: Placebo PIC. |
| Experimental: Cohort 3: 120 mg ALXN2050/Placebo Participants randomized to receive ALXN2050 or placebo BID on Day 1 through Day 14 in a fasted state. | Drug: ALXN2050 Powder-in-capsule (PIC). Other Name: ACH-0145228 (formerly) Other Name: ACH-5228 Drug: Placebo PIC. |
| Experimental: Cohort 4: 200 mg ALXN2050/Placebo Participants randomized to receive ALXN2050 or placebo BID on Day 1 through Day 14 in a fasted state. | Drug: ALXN2050 Powder-in-capsule (PIC). Other Name: ACH-0145228 (formerly) Other Name: ACH-5228 Drug: Placebo PIC. |
| Experimental: Cohort 5: 120 mg ALXN2050/Placebo Participants randomized to receive a single dose of ALXN2050 or placebo on Day 1 in a fed state. | Drug: ALXN2050 Powder-in-capsule (PIC). Other Name: ACH-0145228 (formerly) Other Name: ACH-5228 Drug: Placebo PIC. |
| Experimental: Cohort 6: 240 mg ALXN2050/Placebo Participants randomized to receive a single dose of ALXN2050 or placebo on Day 1 in a fasted state. | Drug: ALXN2050 Powder-in-capsule (PIC). Other Name: ACH-0145228 (formerly) Other Name: ACH-5228 Drug: Placebo PIC. |